title: [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives].
abstract: Pharmacological treatment of acute anxiety still relies on benzodiazepines, while chronic anxiety disorders and depression are treated with different antidepressants, according to specific indications. The monoaminergic axis is represented by two families which are being developed: (i) serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRI), also called triple reuptake inhibitors (TRI), for the treatment of depression (amitifadine), (ii) multimodal antidepressants for depression and anxiety disorders (generalized anxiety disorder mainly) (tedatioxetine, vortioxetine and vilazodone). Third-generation antipsychotics (aripiprazole, lurasidone, brexpiprazole, cariprazine) appear relevant in the treatment of resistant depression and some anxiety disorders. Among the modulators of the glutamatergic axis, promising compounds include: (i) ionotropic regulators of NMDA receptors: esketamine, AVP-923 and AVP-786, CERC-301, rapastinel (Glyx-13), NRX-1074 developed for depression, rapastinel and bitopertine developed for obsessive compulsive disorder, (ii) metabotropic glutamate receptors modulators: decoglurant and basimglurant developed for depression and mavoglurant developed for obsessive compulsive disorder.
authors.affiliation: Référent recherche, établissement public de santé Alsace Nord (EPSAN), 67170 Brumath, France; Réseau PIC - psychiatrie information communication, 59487 Armentières, France; Pharmacopsy Alsace, clinique de psychiatrie, CHU de Strasbourg, 67000 Strasbourg, France. Electronic address: herve.javelot@ch-epsan.fr.
authors.forename: H
authors.initials: H
authors.lastname: Javelot
mesh_terms: D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D011600:Psychopharmacology
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents
keywords: Anxiety; Anxiété; Depression; Dépression; New treatments; Nouveaux traitements